Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 11/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27146563 | 0.85 | LOXL2 (0.54) | MRGPRX4PTPN1FOLH1 | |
| SCHEMBL20356537 | 0.80 | FOLH1 (0.58) | MRGPRX4FOLH1 | |
| SCHEMBL9937700 | 0.79 | NR4A2 (0.54) | PTPN1KDM4CRXRAKDM5AKDM5B | |
| SCHEMBL24484775 | 0.79 | SRD5A2 (0.62) | MRGPRX4FOLH1MEP1B | |
| SCHEMBL15280152 | 0.79 | ACHE (0.48) | — | |
| SCHEMBL19067568 | 0.77 | RXRA (0.47) | MRGPRX4PTPN1FOLH1RXRA | |
| SCHEMBL11827812 | 0.77 | HCAR2 (0.46) | MRGPRX4RXRA | |
| SCHEMBL27145168 | 0.77 | MRGPRX4 (0.58) | MRGPRX4KDM4CKDM5AKDM5B | |
| SCHEMBL22480963 | 0.77 | MRGPRX4 (1.00) | MRGPRX4 | |
| SCHEMBL70351 | 0.76 | FOLH1 (0.70) | FOLH1MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | MRGPRX4 643/4885PTPN1 3963/4885FOLH1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.